Canadian application, no grantCanada
Methods for inhibiting mrp1
CA 2327706 A1 · Owner: Eli Lilly And Company · Inventors: Norman, Bryan, H.; Gruber, Joseph Michael
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a compound of formula (I) which is useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 7, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 7, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 7, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledApril 7, 1999
GrantedNo grant recorded
Term endedApril 7, 2019
Patent numberCA 2327706 A1
Classification (IPC)A61K31/44 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.